AN OBSERVATIONAL STUDY TO ASSESS THE ADVERSE DRUG REACTION OF ANTI-ASTHMATIC DRUGS AMONG ADULTS IN WESTERN RAJASTHAN

NARENDRA KUMAR SWAMI; JIGNESH KUMAR; RASHMI BHUJADE; ANIL SINGH BAGHEL

doi:10.22159/ajpcr.2022.v15i4.44273

Authors

NARENDRA KUMAR SWAMI Department of Pharmacology, Government Medical College, Churu, Rajasthan, India.
JIGNESH KUMAR Department of Pharmacology, Government Medical College, Dungarpur, Rajasthan, India.
RASHMI BHUJADE Department of Community Medicine, S.N. Medical College, Agra, Uttar Pradesh, India. 4Department of Community Medicine, Government Medical College, Dungarpur, Rajasthan, India.
ANIL SINGH BAGHEL Department of Community Medicine, Government Medical College, Dungarpur, Rajasthan, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i4.44273

Keywords:

Bronchial asthma, Anti asthmatic drug, Adverse drug reactions

Abstract

Background: Asthma is one of the most common chronic illness worldwide. For prevention of exacerbations, patients of bronchial asthma are kept on long-term treatment that is why they are amenable for adverse drug reactions (ADRs). The study was planned to monitor ADRs with intervention of anti-asthmatic drugs in adults visited in medicine outpatient or admitted in inpatient department of a tertiary care teaching hospital.

Methods: A cross-sectional study was conducted among 340 asthma patients in collaboration with Department of Medicine for duration of 12 months. Information of patients was collected with the help of semi-structured case record form ADRs along with interventions given that were also recorded.

Results: Data analysis was done with the help of SPSS version20.0. Fisher exact test was applied. A total of 340 patients were enrolled in the study. The highest numbers of ADRs were observed with Salbutamol (34.78%). The highest ADRs were noted with Beta2 agonists class of drugs. The main ADRs noted were headache followed by tremors and oral thrush. Statistically significant association was found between presence of ADRs and severity of asthma.

Conclusion: Identifying any possible connection between a presenting complaint and drug used is crucial to reduce the risk of ADRs in the future. Appropriate monitoring of ADRs is a key for this. Reduction in ADRs will improve the compliance of patient and ultimately their clinical outcome.

Downloads

Download data is not yet available.

References

Satoskar RS, Rege NN, Bhandarkar SD. Pharmacology and Pharmacotherapeutics. 24th ed., Vol. 361. India: Elsevier; 2015.

Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma (GINA) Program. The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78.

McFadden ER Jr. Harrison’s Principles of Internal Medicine. 16th ed. United States: McGraw-Hill; 2005. p. 1508-16.

Pascual R, Johnson JR, Peters SP. Fishman’s Pulmonary Disease and Disorders .4th ed. United States: McGraw-Hill; 200. p. 815-36.

WHO. Requirements for Adverse drug Reaction Reporting. Geneva: World Health Organization; 1975. p. 1039-109.

Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008;32:545-54.

Agrawal S, Pearce N, Ebrahim S. Prevalence and risk factors for self-reported asthma in an adult Indian population: A cross-sectional survey. Int J Tuberc Lung Dis 2013;17:275-82.

Jamali AN, Aqil M, Alam MS, Pillai KK, Kapur P. A pharmacovigilance study on patients of bronchial asthma in a teaching hospital. J Pharm Bioallied Sci 2010;2:333-6.

Barranco P, López-Serrano MC. General and epidemiological aspects of allergic drug reactions. Clin Exp Allergy 1998;28 Suppl 4:61-2.

Riedl MA, Casillas AM. Adverse drug reactions: Types and treatment options. Am Fam Physician 2003;68:1781-90.

Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Piñeiro A, Wei LX, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/ Beclomethasone Study Group. Ann Intern Med 1999;130:487-95.

Meltzer EO, Lockey RF, Friedman BF, Kalberg C, Goode-Sellers S, Srebro S, et al. Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma. Mayo Clin Proc 2002;77:437-45.

Habashy D, Lam LT, Browne GJ. The administration of beta2-agonists for paediatric asthma and its adverse reaction in Australian and New Zealand emergency departments: A cross-sectional survey. Eur J Emerg Med 2003;10:219-24.

Gawali UP, Deshkar A. Pharmacovigilance study of anti-asthmatic agents in patients of bronchial asthma at a tertiary care centre. Int J Adv Res 2017;5:1867-71.

Bhosale U, Jaiswal S, Yegnanarayan R, Godbole G. A pharmacovigilance study of anti-asthmatic agents in patients of bronchial asthma at a tertiary care hospital. J Clin Exp Res 2013;1:26-30.

Muthukumar A, Sundara Ganapathy R. A study on adverse drug reactions and their risk factors of anti-asthmatic agents among garments dust-induced asthmatic patients in Manchester of south India. Asian J Pharm Clin Res 2018;11:130-2.

Padmaja SY, Palaniswamy S. A study on assessment, monitoring and documentation of adverse drug reactions. Int J Pharm Teach Pract 2012;3:253-6.

Babu SN, Kumar CV, Nandini R. Comparative study of adverse drug reaction pattern of two anti-asthma groups of drugs in a tertiary care hospital. Int J Basic Clin Pharmacol 2019;8:788-91.